Current management of cardiac transplant recipients.
- 1 December 1979
- Vol. 42 (6), 703-708
- https://doi.org/10.1136/hrt.42.6.703
Abstract
Changes in the management of cardiac transplant recipients over the past 10 years have resulted in a substantial improvement in the outlook for survival. Imuran and prednisone remain the primary immunosuppressive agents, but rabbit antihuman thymocyte globulin is used initially and reinstituted during rejection. Endomyocardial biopsy has allowed more precise diagnosis and management of rejection, and more recently immunological monitoring has been introduced to provide more frequent assessment of the host immune response. Infection is the major cause of death, and its diagnosis and treatment is managed aggressively. Current survival figures justify the use of cardiac transplantation, by an experienced team, when other measures have been exhausted.This publication has 11 references indexed in Scilit:
- Malignant Neoplasms Following Cardiac TransplantationJAMA, 1978
- Relationship of rabbit ATG serum clearance rate to circulating T-cell level, rejection onset, and survival in cardiac transplantation.1977
- Heart and other organs. Increasing patient survival following heart transplantation.1977
- CONTROL OF GRAFT ARTERIOSCLEROSIS IN HUMAN HEART-TRANSPLANT RECIPIENTS1977
- USE OF RABBIT ANTITHYMOCYTE GLOBULIN IN CARDIAC TRANSPLANTATIONTransplantation, 1976
- RADIOIMMUNE ASSAY OF HETEROLOGOUS SERUM γ-GLOBULIN IN PATIENTS RECEIVING RABBIT ANTIHUMAN THYMOCYTE GLOBULINTransplantation, 1975
- Diagnosis of human cardiac allograft rejection by serial cardiac biopsyThe Journal of Thoracic and Cardiovascular Surgery, 1973
- Cardiac transplantation in man. I. Early rejection.1969
- Cardiac Transplantation in ManPublished by American Medical Association (AMA) ,1969